Skip to main content

NCI Grants BioMarker Strategies SBIR Funds

NEW YORK (GenomeWeb News) – BioMarker Strategies, a molecular diagnostics developer focused on tumor testing, has won a Small Business Innovation Research grant from the National Cancer Institute.

The Fast-Track SBIR grant gives the company an initial award of $254,000, a number that could increase by up to $2 million after the initial phase of the work is completed, the firm said.

The company plans to use the funds to "expedite production" of a prototype of its SnapPath live-tumor cell testing system, BioMarker Strategies CEO Karen Olson said in a statement.

Based in the Johns Hopkins Science and Technology Park in Baltimore, Md., BioMarker Strategies also is developing a series of pathway-based ex-vivo biomarker tests to guide targeted cancer therapeutics.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.